Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 12, 2011, Pages 3695-3700

  Yim, Ji Hye ^a   Kim, Won Bae ^a   Kim, Eui Young ^a   Kim, Won Gu ^a   Kim, Tae Yong ^a   Ryu, Jin Sook ^a   Moon, Dae Hyuk ^a   Sung, Tae Yon ^a   Yoon, Jong Ho ^a   Kim, Seong Chul ^a   Hong, Suck Joon ^a   Shong, Young Kee ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; REOPERATION; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADULT; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REOPERATION; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 83155177212     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1270     Document Type: Article

References (16)

1. Jossart GH, Clark OH 1994 Well-differentiated thyroid cancer. Curr Probl Surg 31:933-1012
2. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428 (Pubitemid 24345593)
3. Palme CE, Waseem Z, Raza SN, Eski S, Walfish P, Freeman JL 2004 Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 130:819-824 (Pubitemid 38915967)
4. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55:794-804 (Pubitemid 15173518)
5. Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH, Chung EJ 2010 Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid 20:147-152
6. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A 2004 A novel classification system for patients with PTC: addition of thenewvariables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135:139-148 (Pubitemid 38130764)
7. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
8. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK 2005 Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:1440-1445
9. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A 2001 Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:5686-5690 (Pubitemid 33152608)
10. Pelttari H, Välimäki MJ, Löyttyniemi E, Schalin-Jäntti C 2010 Postablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study. Eur J Endocrinol 163:757-763
11. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A 2001 Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86:4092-4097 (Pubitemid 32848518)
12. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR 2003 Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13:3-126
13. Yim JH, Kim WB, Kim EY, Kim WG, Kim TY, Ryu JS, Gong G, Hong SJ, Shong YK 2011 The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. J Clin Endocrinol Metab 96:2049-2056
14. Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, Ryu JS, Gong G, Hong SJ, Shong YK 2008 Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 93:4683-4689
15. R Development Core Team 2007 R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing
16. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88:1107-1111 (Pubitemid 36337763)